Michael Sundborg, MD
Gynecologic Oncology · Southern Pines, NCNPI 1508857962
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $56,600 of the $85,420 with a category attached, or 66.3%. 20 manufacturers reported payments, led by Tesaro, Inc. at 46.5% of the total. Reporting peaked in 2019 at $39,903 and has fallen 95.1% since, to $1,970 in 2025. Among gynecologic oncology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 177 payments — averaging $482.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tesaro, Inc.$40K
- GSK$37K
- AstraZeneca$5K
- Intuitive Surgical$2K
- Genmab U.S., Inc.$285
- Eisai Inc.$285
- plus $963 from 14 others
Across 21 payments — averaging $21,494 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$188K
- Merck$168K
- Regeneron$67K
- GSK$27K
- Janssen Research & Development, LLC$1K
What the payments were for
- Consulting fees$11,75514%
- Speaking & faculty fees$56,60066%
- Travel & lodging$12,28814%
- Food & beverage$4,6415%
- Education$1360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tesaro, Inc. | 54 | $39,747 |
| GSK | 32 | $37,156 |
| AstraZeneca | 22 | $5,233 |
| Intuitive Surgical | 21 | $1,751 |
| Genmab U.S., Inc. | 7 | $285 |
| Eisai Inc. | 8 | $285 |
| Smith+Nephew | 4 | $180 |
| Merck | 7 | $155 |
| Menarini Silicon Biosystems, Inc. | 1 | $125 |
| Astellas Pharma US Inc | 6 | $122 |
| Myriad Genetic Laboratories, Inc. | 3 | $105 |
| AbbVie | 4 | $92 |
| Johnson & Johnson | 1 | $33 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Immunogen, Inc. | 1 | $29 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $20 |
| Novartis | 1 | $19 |
| Clovis Oncology, Inc. | 1 | $18 |
| Foundation Medicine, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEJULA$72,470
- LYNPARZA$3,652
- JEMPERLI$3,200
- Da Vinci Surgical System$1,375
- GRAFIX PL$125
- Oasis$125
- Stravix$125
- CELLSEARCH$125
- LENVIMA$125
- TIVDAK$116
How this compares
$85,420 in reported general payments places this provider in the 90th percentile of 52 gynecologic oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZejulaNiraparib Tosylate | 13 | $223,230 |
| EliquisApixaban | 37 | $21,926 |
| Megestrol Acetate | 37 | $2,752 |
| Estradiol | 62 | $1,588 |
| Potassium Chloride | 33 | $939 |
| Gabapentin | 51 | $676 |
| Medroxyprogesterone Acetate | 55 | $498 |
| Ondansetron Hcl | 106 | $470 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 34 | $441 |
| Prochlorperazine Maleate | 47 | $433 |
| Dexamethasone | 78 | $319 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 17 | $201 |
| Nystatin | 13 | $185 |
| Oxybutynin Chloride ErOxybutynin Chloride | 15 | $120 |
| Oxycodone Hcl | 14 | $98 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKZejula | $37,156 | $223,23013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 52 gynecologic oncology providers in North Carolina.
Other gynecologic oncology in Southern Pines
- Lucybeth Nieves ArribaWilmington$251K
- Robert NaumannCharlotte$221K
- Angeles SecordDurham$121K
- Erin CraneCharlotte$98K
- William LoweryDurham$67K
- Emma RossiGreensboro$62K
- Jubilee BrownCharlotte$44K
- Victoria Bae-JumpChapel Hill$19K
- Andrew BerchuckDurham$12K
- John McDonaldCharlotte$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.